DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy

Not Applicable

Completed

Conditions: Breast Cancer
Breast Cancer Female
Breast Carcinoma

Interventions: Behavioral: Endocrine Therapy Education Program

First Posted Date: 2024-02-07

Last Posted Date: 2025-01-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 76

Registration Number: NCT06246084

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

CV CARE: CardioVascular Care in PC Patients

Not Applicable

Recruiting

Conditions: Cardiovascular Diseases
Prostate Cancer

Interventions: Behavioral: CV Care Program

First Posted Date: 2024-01-12

Last Posted Date: 2024-07-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 180

Registration Number: NCT06202820

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial

Not Applicable

Recruiting

Conditions: Colorectal Cancer
Metastatic Colon Cancer
Metastatic Colorectal Cancer

Interventions: Behavioral: Exercise Program

First Posted Date: 2024-01-11

Last Posted Date: 2024-07-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 84

Registration Number: NCT06202183

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

CIML NK Cells With Venetoclax for AML

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia
Acute Myeloid Leukemia Recurrent
Leukemia, Myeloid
Leukemia

Interventions: Biological: Cytokine-Induced Memory-like Natural Killer Cells
Biological: Interleukin-2
Drug: Venetoclax

First Posted Date: 2023-12-01

Last Posted Date: 2025-03-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT06152809

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Recruiting

Conditions: Unresectable Bladder Carcinoma
Bladder Cancer
Metastatic Bladder Cancer
Urothelial Carcinoma

Interventions: Behavioral: Geriatric-8 Survey
Behavioral: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)
Behavioral: Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)

First Posted Date: 2023-11-18

Last Posted Date: 2024-04-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 180

Registration Number: NCT06138561

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Phase 1

Recruiting

Conditions: Myeloproliferative Neoplasm
Leukemia
Myeloproliferative Disorders
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Leukemia, Myeloid

Interventions: Biological: Cytokine Induced Memory-like Natural Killer Cells
Biological: Interleukin-2

First Posted Date: 2023-11-18

Last Posted Date: 2024-12-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT06138587

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Early Phase 1

Recruiting

Conditions: Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
Pancreatic Neoplasm

Interventions: Other: Screening Blood Tests
Diagnostic Test: Endoscopic Ultrasound
Combination Product: Magnetic Resonance Imaging
Combination Product: Magnetic Resonance Cholangiopancreatography

First Posted Date: 2023-11-08

Last Posted Date: 2025-03-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5000

Registration Number: NCT06122896

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing

Not Applicable

Not yet recruiting

Conditions: Advanced Cancer
Pain

Interventions: Behavioral: I-STAMP

First Posted Date: 2023-11-07

Last Posted Date: 2025-04-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 73

Registration Number: NCT06117709

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma As a Prognostic and Response Diagnostic: LEOPARD

Not Applicable

Recruiting

Conditions: Ewing Sarcoma of Soft Tissue
Ewing Sarcoma of Bone
Peripheral Primitive Neuroectodermal Tumor of Bone
Peripheral Primitive Neuroectodermal Tumor of Soft Tissue
Peripheral Primitive Neuroectodermal Tumor
Ewing Sarcoma
High-grade Osteosarcoma

Interventions: Other: FoundationOne Liquid CDx

First Posted Date: 2023-10-05

Last Posted Date: 2025-01-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 340

Registration Number: NCT06068075

Locations: 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 12 locations

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial

Not Applicable

Recruiting

Conditions: PROSTATE CANCER
Metastatic Prostate Carcinoma
Metastatic Prostate Cancer

Interventions: Behavioral: Supervised Circuit Training

First Posted Date: 2023-09-15

Last Posted Date: 2025-02-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 80

Registration Number: NCT06040125

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy